Boit C F David Sells 800 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Boit C F David reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 34.8% in the second quarter, HoldingsChannel.com reports. The firm owned 1,500 shares of the medical equipment provider’s stock after selling 800 shares during the period. Boit C F David’s holdings in Zimmer Biomet were worth $137,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC boosted its position in shares of Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after purchasing an additional 118 shares during the period. Chicago Partners Investment Group LLC boosted its position in shares of Zimmer Biomet by 3.3% during the second quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock worth $376,000 after acquiring an additional 124 shares during the last quarter. Private Trust Co. NA boosted its position in shares of Zimmer Biomet by 14.6% during the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock worth $98,000 after acquiring an additional 137 shares during the last quarter. Brooklyn Investment Group boosted its position in shares of Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in shares of Zimmer Biomet by 8.3% during the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after acquiring an additional 149 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of a number of research reports. UBS Group upped their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Raymond James Financial upped their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Evercore ISI dropped their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Finally, Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $111.94.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.70% of the company’s stock.

Zimmer Biomet Trading Down 0.0%

Shares of ZBH opened at $102.70 on Wednesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72. The company has a market cap of $20.34 billion, a P/E ratio of 24.99, a P/E/G ratio of 2.36 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The company’s fifty day simple moving average is $101.82 and its 200-day simple moving average is $97.68.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the firm posted $2.01 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.